Pharmaceuticals News and Research

RSS

New therapeutic approach for treating type 2 diabetes

Scientists from the Helmholtz Zentrum München (HMGU) and the Technische Universität München (TUM), together with scientists in the USA, have developed a new therapeutic approach for treatment of type 2 diabetes.

31 Oct 2013

Cardinal Health's non-GAAP operating earnings increase 13% to $532M in Q1 FY 2014

Cardinal Health today reported fiscal year 2014 first-quarter revenue of $24.5 billion and a 36 percent increase in non-GAAP diluted earnings per share (EPS) from continuing operations to $1.10. Non-GAAP operating earnings increased 13 percent to $532 million.

31 Oct 2013

Actavis seeks FDA approval to market Isotretinoin Capsules

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Isotretinoin Capsules, 10 mg, 20 mg, 30 mg and 40 mg.

31 Oct 2013

Valeant Pharmaceuticals' total revenues increase 74% to $1.54B in Q3 2013

Valeant Pharmaceuticals International, Inc. announces third quarter financial results for 2013. "Despite an unexpected early launch of a generic Retin-A Micro, significant headwinds this quarter from foreign exchange movements, and the demands of a major integration, we managed to beat expectations and position Valeant for a terrific fourth quarter and a strong 2014," stated J. Michael Pearson, chairman and chief executive officer.

31 Oct 2013

Novaquest closes $459 million private equity fund

NovaQuest Capital Management, L.L.C. is pleased to announce the final closing of NovaQuest Pharma Opportunities Fund III, L.P., a $459 million private equity fund focused on providing structured finance solutions to biopharmaceutical companies ("Fund III").

31 Oct 2013

Mylan's revenues decrease 2% to $1.77B in third quarter 2013

Mylan Inc. today announced its financial results for the three and nine months ended September 30, 2013.

31 Oct 2013

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.

31 Oct 2013

Alkermes reports 38% of year-over-year revenue growth from key products

Alkermes plc today reported financial results for the quarter ended Sept. 30, 2013. This is the second quarter of the nine-month period ending Dec. 31, 2013, as the company transitions to reporting on a calendar year basis.

31 Oct 2013

Rat study shows compulsive gambling behaviours can be reduced in humans

With the help of a rat casino, University of British Columbia brain researchers have successfully reduced behaviours in rats that are commonly associated with compulsive gambling in humans.

31 Oct 2013

Scientists develop new therapeutic approach for treatment of type 2 diabetes

Scientists from the Helmholtz Zentrum Muenchen and the Technische Universitaet Muenchen, together with scientists in the USA, have developed a new therapeutic approach for treatment of Type 2 diabetes. A novel single molecule hormone, which acts equally on the receptors of the insulin-stimulating hormones GLP-1 and GIP, was observed to reduce weight and improve blood sugar.

31 Oct 2013

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

31 Oct 2013

Immune Design closes Series C financing totalling up to $49M

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million.

30 Oct 2013

New analysis shows that 29% of clinical trial results remain unpublished

A new analysis of 585 large, randomized clinical trials registered with ClinicalTrials.gov finds that 29 percent have not been published in scientific journals. In addition, nearly 78 percent of the unpublished trials had no results available on the website, either.

30 Oct 2013

ETPN organizes Nanomedicine Award to honor the best international innovation for 2013

Since the official launch in June 2013, the European Technology Platform for Nanomedicine (ETPN) together with the EU funded consortium NANOMED2020, are organising the first ever Nanomedicine Award to honor the best international nanomedicine innovation for 2013!

30 Oct 2013

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

30 Oct 2013

Researchers develop new substance that quickly and effectively kills multi-resistant bacteria

In Europe alone, more than 25,000 people die each year from infections caused by multi-resistant bacteria. Researchers from University of Copenhagen have now developed and characterized a substance that quickly and effectively kills the virulent bacteria. The substance employs a multifunctional mechanism that reduces the risk of antibiotic resistance. The findings have recently been published in the scientific journal Chemistry & Biology.

30 Oct 2013

Researchers identify new drug for treating irritable bowel syndrome with constipation

An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

30 Oct 2013

Sanovas receives patent for Multi-Balloon Catheter for Extravasated Drug Delivery

Sanovas Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office issued patent # 8,540,667 for the company's Multi-Balloon Catheter for Extravasated Drug Delivery.

29 Oct 2013

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Firstly, actinic keratosis (AK) is a common dermatological condition caused by cumulative exposure to the sun. Providing patients with effective treatment is very important, as AK can lead to forms of non-melanoma skin cancer (NMSC) if not diagnosed and treated early. In fact, two in three cases of squamous cell carcinoma (a common form of skin cancer), begin as AK.

29 Oct 2013

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').

29 Oct 2013

Pharmaceuticals News and Research

New therapeutic approach for treating type 2 diabetes

Cardinal Health's non-GAAP operating earnings increase 13% to $532M in Q1 FY 2014

Actavis seeks FDA approval to market Isotretinoin Capsules

Valeant Pharmaceuticals' total revenues increase 74% to $1.54B in Q3 2013

Novaquest closes $459 million private equity fund

Mylan's revenues decrease 2% to $1.77B in third quarter 2013

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

Alkermes reports 38% of year-over-year revenue growth from key products

Rat study shows compulsive gambling behaviours can be reduced in humans

Scientists develop new therapeutic approach for treatment of type 2 diabetes

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

Immune Design closes Series C financing totalling up to $49M

New analysis shows that 29% of clinical trial results remain unpublished

ETPN organizes Nanomedicine Award to honor the best international innovation for 2013

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Researchers develop new substance that quickly and effectively kills multi-resistant bacteria

Researchers identify new drug for treating irritable bowel syndrome with constipation

Sanovas receives patent for Multi-Balloon Catheter for Extravasated Drug Delivery

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence